Panacea Biotec obtains patent for extended release

2206 Investors following Panacea Biotec. Share this News with them.

0

Like this story, share it with millions of investors on M3

Panacea Biotec obtains patent for extended release

Panacea Biotec obtains patent for extended release* pharmaceutical composition containing Nimesulide (WILLGO)

Post your opinion here

 

0

Tweet

Share on Tumblr

ALSO READ See latest News about Panacea Biotec See previous management interviews See what other Experts & Brokerages are saying about Panacea Biotec Panacea Biotec BSE | NSE 25/05/12 Are Mutual Funds betting on Panacea Biotec?

Panacea Biotec, a leading research based health management company has been granted patent by Govt. of India, for invention entitled process for the preparation of 'Extended Release* Pharmaceutical Composition Containing Nimesulide' for 20 years in accordance with the provisions of the Patents Act, 1970. 

Nimesulide is one of the most widely prescribed non-steroidal anti-inflammatory drugs (NSAIDs) with excellent analgesic, antipyretic and safety profile. It has a unique mechanism of action when compared to other NSAIDs. Panacea Biotec launched its 'Extended Release* Nimesulide' under the brand name 'WILLGO' in 2004 in India. 'WILLGO' has recorded a growth rate of around 48% over last year (ORG IMS June'06).

"The recent grant of Extended Release* Nimesulide (WILLGO) Patent has greatly boosted our morale to keep up our efforts in developing novel & innovative drug delivery systems through our R&D efforts. 'WILLGO' provides effective management of Osteoarthritis by providing continuous relief from chronic joint pain in osteoarthritis patients. 'WILLGO' offers excellent patient compliance, as only one tablet needs to be taken at bedtime. We have already received this Patent in 10 countries so far, out of 34 countries, where Patent applications have been filed," says  Mr. Rajesh Jain, Joint Managing Director, Panacea Biotec.

'WILLGO' provides effective relief from joint pain & stiffness, swelling & tenderness, which leads to improved functional mobility in patients of osteoarthritis, enabling them to perform daily functional activities.

The size of the global NSAID market is around USD 11 Billion annually (Source: IMS MIDAS Quantum, June'05). Between 2000-2005, NSAIDs categorized as Coxibs (Celecoxib, Rofecoxib, Valdecoxib, Etoricoxib) were the most preferred NSAIDs in management of Osteoarthritis. After the withdrawal of various Coxibs from the international and domestic markets in 2005, 'WILLGO' would fit into the bill with its efficacy, good tolerability and convenient once daily dosage for osteoarthritis patients. The total NSAID market in India is estimated at Rs.1034 crores annually. Nimesulide is the largest selling single ingredient NSAID in oral dosage form, having a market of around Rs. 126 crores, annually in India (Source: ORG IMS-May'06).

*Also known as 'Controlled Release'

Sourced From :Imprimis Life PR